Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?
Adolescent
Adult
Aged
Carrier State
/ blood
Cohort Studies
DNA, Viral
/ blood
Disease Progression
Female
Genotype
Hepatitis B
/ blood
Hepatitis B Surface Antigens
/ analysis
Hepatitis B e Antigens
/ blood
Hepatitis B virus
/ genetics
Humans
Male
Middle Aged
Mutation
Quasispecies
Serologic Tests
Viremia
/ blood
Young Adult
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
25
10
2019
revised:
19
11
2019
accepted:
06
04
2020
pubmed:
12
5
2020
medline:
24
11
2020
entrez:
12
5
2020
Statut:
ppublish
Résumé
Virus, host factors and their interplay influence Hepatitis B surface Antigen serum levels during Hepatitis B Virus (HBV) infection course and treatment. To study the Pre-S/S circulating quasispecies in a cohort of untreated, HBeAg negative, genotype-D, HBsAg carriers. We studied 260 carriers: 71 with HBeAg negative infection (ENI; HBV-DNA ≤2000 IU/mL); 42 Grey Zone (GZ; HBV-DNA ≤20 000 IU/mL); 82 chronic hepatitis (CH) and 65 cirrhosis (CI) (HBV-DNA > 20 000 IU/mL). Population sequencing was applied to identify Pre-S/S gene mutations responsible for any amino acid substitution or potential biological/antigenic implications (M-muts) on HBsAg. HBsAg serum levels were lower in ENI + GZ than in CH + CI (2.61 [-1.10/4.06] vs 3.62 [2.41/4.92] log In HBeAg negative, genotype-D, carriers Pre-S/S heterogeneity increases with severity of liver disease, but does not influence HBsAg serum levels, that in low viraemic carriers are associated with an effective control of HBV.
Sections du résumé
BACKGROUND
Virus, host factors and their interplay influence Hepatitis B surface Antigen serum levels during Hepatitis B Virus (HBV) infection course and treatment.
AIM
To study the Pre-S/S circulating quasispecies in a cohort of untreated, HBeAg negative, genotype-D, HBsAg carriers.
METHODS
We studied 260 carriers: 71 with HBeAg negative infection (ENI; HBV-DNA ≤2000 IU/mL); 42 Grey Zone (GZ; HBV-DNA ≤20 000 IU/mL); 82 chronic hepatitis (CH) and 65 cirrhosis (CI) (HBV-DNA > 20 000 IU/mL). Population sequencing was applied to identify Pre-S/S gene mutations responsible for any amino acid substitution or potential biological/antigenic implications (M-muts) on HBsAg.
RESULTS
HBsAg serum levels were lower in ENI + GZ than in CH + CI (2.61 [-1.10/4.06] vs 3.62 [2.41/4.92] log
CONCLUSIONS
In HBeAg negative, genotype-D, carriers Pre-S/S heterogeneity increases with severity of liver disease, but does not influence HBsAg serum levels, that in low viraemic carriers are associated with an effective control of HBV.
Substances chimiques
DNA, Viral
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1406-1416Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398-411.
Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483-490.
Liu J, Yang HI, Lee MH, et al. Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression. Hepatology. 2016;64:381-389.
Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141-1150.
Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49:1151-1157.
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64:51-68.
Dienes HP, Gerlich WH, Worsdorfer M, et al. Hepatic expression patterns of the large and middle hepatitis B surface proteins in viremic and non viremic chronic hepatitis B. Gastroenterology. 1990;98:1017-1023.
Lau JYN, Bain VG, Davies SE, Alexander GJM, Williams R. Export of intracellular HBsAg in chronic hepatitis B virus infection is related to viral replication. Hepatology. 1991;3:416-421.
Pfefferkorn M, Böhm S, Schott T, et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut. 2018;67:2045-2053.
Simon K, Lingappa VR, Ganem D. Secreted hepatitis B surface antigen polypeptides are derived from transmembrane precursor. J Cell Biol. 1988;107:2163-2168.
Fernholz D, Stemler M, Brunetto M, Bonino F, Will H. Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein. J Hepatol. 1991;13(Suppl 4):S102-S104.
Bruss V, Gerhardt E, Vieluf K, Wunderlich G. Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology. 1996;39:23-31.
Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology. 1993;194(1):137-148.
Pollicino T, Zanetti AR, Cacciola I, et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology. 1997;26:495-499.
De Medina T, Kaktor O, Shaul Y. The S promoter of HBV is regulated by positive and negative elements. Mol Cell Biol. 1988;8:2449-2455.
Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol. 2010;84:1989-2000.
Stibbe W, Gerlich WH. Structural relationship between minor and major proteins of hepatitis B surface antigen. J Virol. 1983;46:626-628.
Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of HBV containing the Pre-s sequence. J Virol. 1984;52:396-402.
Lentz TB, Loeb DD. Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol. 2011;85:11916-11927.
Garcia T, Li J, Sureau C, et al. Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. J Virol. 2009;83:11152-11165.
Brunetto MR, Marcellin P, Cherubini B, et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol. 2013;59:1153-1159.
Malve B, Eschlimann M, Galgey S, et al. Impact of deletions and mutations in Hepatitis B virus envelope proteins on serological profile and clinical evolution. Virus Res. 2017;238:141-147.
Lin CM, Wang GM, Jow GM, Chen BF. Functional analysis of hepatitis B virus pre-s deletion variants associated with hepatocellular carcinoma. J Biomed Sci. 2012;19:17.
Chen CH, Hung CH, Lee CM, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 2007;133:1466-1474.
Yeung P, Wong DK, Lai CL, Fung J, Seto WK, Yuen MF. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 2011;203:646-654.
Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014;61:408-417.
Fan YF, Lu CC, Chen WC, et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology. 2001;33:277-286.
Pollicino T, Amaddeo G, Restuccia A, et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology. 2012;56:434-443.
Wooddell CI, Yuen M-F, Chan H-Y, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017;9:1-22.
Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. HBVdb: a knowledge database for hepatitis B virus. Nucleic Acids Res. 2013;41:D566-D570.
Kuhnhenn L, Jiang B, Kubesch A, et al. Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection. Aliment Pharmacol Ther. 2018;47:1523-1535.
Chen BF. Different pre-S deletion patterns and their association with hepatitis B virus genotypes. World J Gastroenterol. 2016;22:8041-8049.
Colombatto P, Barbera C, Bortolotti F, et al. HBV pre-core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood. J Med Virol. 2018;90:1232-1239.
Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA. 1991;88:4186-4190.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-352.
Glebe D, Urban S, Knoop EV, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology. 2005;129:234-245.
Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology. 2006;130:1153-1168.
Melegari M, Scaglioni PP, Wands JR. The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol. 1997;71:5449-5454.
Peiffer K-H, Kuhnhenn L, Jiang B, et al. Divergent preS sequences in virion-associated hepatitis B virus genomes and subviral HBV surface antigen particles From HBV e antigen-negative patients. J Infect Dis. 2018;218:144-223.